February 20th 2024
A panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.
February 13th 2024
A panel of experts discuss how to sequence BTK inhibitors and CAR T-cell therapies in patients with MCL.
Experts on mantle cell lymphoma discuss third-line treatment options available for patients.
February 6th 2024
Experts on mantle cell lymphoma discuss second-line treatment options available for patients.
A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline MCL.
January 30th 2024
Experts on mantle cell lymphoma discuss first-line treatment options available for patients.
Laurie Sehn, MD, and Bijal Shah, MD, discuss remaining unmet needs for patients with relapsed/refractory FL.
January 23rd 2024
Peter Martin, MD, discusses how to sequence bispecific T-cell engagers and CAR T-cell therapies in the third-line and beyond setting for FL.
Jennifer Crombie, MD, discusses how to choose CAR T-cells as third-line and beyond therapy for FL.
January 16th 2024
A panel of experts discuss how to choose bispecific T-cell engagers as third-line and beyond therapy for FL.
Laurie Sehn, MD, discusses recent data on zanubrutinib, a BTK inhibitor, as third-line and beyond therapy for FL.
January 10th 2024
Peter Martin, MD, discusses recent data on tazemetostat, an EZH2 inhibitor, as third-line and beyond therapy for FL.
Matthew Lunning, DO, discusses recent data on bispecific T-cell engagers as third-line and beyond therapy for FL.
August 3rd 2022
Matthew A. Lunning, DO, FACP, discusses trials evaluating BTK inhibitors in chronic lymphocytic leukemia.
June 2nd 2021
Matthew Lunning, DO, discusses the efficacy of axicabtagene ciloleucel in patients with relapsed/refractory indolent non-Hodgkin lymphoma.
November 10th 2020
Matthew A. Lunning, DO, discusses initial treatment considerations in chronic lymphocytic leukemia.
July 23rd 2018
Matthew A. Lunning, DO, assistant professor, Internal Medicine Division of Oncology & Hematology, University of Nebraska Medical Center, discusses the treatment of patients with peripheral T-cell lymphoma.